A phase I, open-label, multi-center study of the JAK2 inhibitor AZD1480 in patients with myelofibrosis

Srdan Verstovsek, Ronald Hoffman, John Mascarenhas, Jean Charles Soria, Ratislav Bahleda, Patricia McCoon, Weifeng Tang, Jorge Cortes, Hagop Kantarjian, Vincent Ribrag

Research output: Contribution to journalArticle

Abstract

The anti-tumor activity of AZD1480, a potent, selective inhibitor of Janus-associated kinases 1 and 2, was demonstrated in preclinical models of myeloproliferative neoplasms. In a phase I clinical study, 35 patients with myelofibrosis received 2.5-70. mg AZD1480 orally once daily (QD) or 10 or 15. mg twice daily (BID) continuously during repeated 28-day cycles. Two patients experienced dose-limiting toxicities: one patient in the 2.5. mg QD cohort had a grade 3 lung infiltration/acute pneumonia, and one patient receiving 50. mg QD had grade 3 presyncope. Dosing was stopped at 70. mg QD after the first patient experienced an adverse neurological event (AE) and evidence of low-grade neurological toxicity in patients on lower doses after the initial month of therapy became apparent. The most common AZD1480-related AEs were dizziness and anemia. AZD1480 was absorbed quickly and eliminated from the plasma rapidly, with a mean terminal half-life of 2.45-8.06. h; accumulation was not observed after repeated daily dosing for 28 days. Four patients showed evidence of clinical improvement based on IWG-MRT 2006 criteria. AZD1480 was relatively well tolerated, however, low-grade, reversible neurological toxicity was therapy limiting and led to study termination.

Original languageEnglish (US)
Pages (from-to)157-163
Number of pages7
JournalLeukemia Research
Volume39
Issue number2
DOIs
StatePublished - Feb 1 2015
Externally publishedYes

Fingerprint

Primary Myelofibrosis
Janus Kinase 1
Janus Kinase 2
Syncope
Dizziness
AZD 1480
Half-Life
Anemia
Neoplasms
Pneumonia
Lung
Therapeutics

Keywords

  • AZD1480
  • JAK2 mutation
  • Myelofibrosis

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Verstovsek, S., Hoffman, R., Mascarenhas, J., Soria, J. C., Bahleda, R., McCoon, P., ... Ribrag, V. (2015). A phase I, open-label, multi-center study of the JAK2 inhibitor AZD1480 in patients with myelofibrosis. Leukemia Research, 39(2), 157-163. https://doi.org/10.1016/j.leukres.2014.11.018

A phase I, open-label, multi-center study of the JAK2 inhibitor AZD1480 in patients with myelofibrosis. / Verstovsek, Srdan; Hoffman, Ronald; Mascarenhas, John; Soria, Jean Charles; Bahleda, Ratislav; McCoon, Patricia; Tang, Weifeng; Cortes, Jorge; Kantarjian, Hagop; Ribrag, Vincent.

In: Leukemia Research, Vol. 39, No. 2, 01.02.2015, p. 157-163.

Research output: Contribution to journalArticle

Verstovsek, S, Hoffman, R, Mascarenhas, J, Soria, JC, Bahleda, R, McCoon, P, Tang, W, Cortes, J, Kantarjian, H & Ribrag, V 2015, 'A phase I, open-label, multi-center study of the JAK2 inhibitor AZD1480 in patients with myelofibrosis', Leukemia Research, vol. 39, no. 2, pp. 157-163. https://doi.org/10.1016/j.leukres.2014.11.018
Verstovsek, Srdan ; Hoffman, Ronald ; Mascarenhas, John ; Soria, Jean Charles ; Bahleda, Ratislav ; McCoon, Patricia ; Tang, Weifeng ; Cortes, Jorge ; Kantarjian, Hagop ; Ribrag, Vincent. / A phase I, open-label, multi-center study of the JAK2 inhibitor AZD1480 in patients with myelofibrosis. In: Leukemia Research. 2015 ; Vol. 39, No. 2. pp. 157-163.
@article{f3b8309387764f039d87f68c5b7b535a,
title = "A phase I, open-label, multi-center study of the JAK2 inhibitor AZD1480 in patients with myelofibrosis",
abstract = "The anti-tumor activity of AZD1480, a potent, selective inhibitor of Janus-associated kinases 1 and 2, was demonstrated in preclinical models of myeloproliferative neoplasms. In a phase I clinical study, 35 patients with myelofibrosis received 2.5-70. mg AZD1480 orally once daily (QD) or 10 or 15. mg twice daily (BID) continuously during repeated 28-day cycles. Two patients experienced dose-limiting toxicities: one patient in the 2.5. mg QD cohort had a grade 3 lung infiltration/acute pneumonia, and one patient receiving 50. mg QD had grade 3 presyncope. Dosing was stopped at 70. mg QD after the first patient experienced an adverse neurological event (AE) and evidence of low-grade neurological toxicity in patients on lower doses after the initial month of therapy became apparent. The most common AZD1480-related AEs were dizziness and anemia. AZD1480 was absorbed quickly and eliminated from the plasma rapidly, with a mean terminal half-life of 2.45-8.06. h; accumulation was not observed after repeated daily dosing for 28 days. Four patients showed evidence of clinical improvement based on IWG-MRT 2006 criteria. AZD1480 was relatively well tolerated, however, low-grade, reversible neurological toxicity was therapy limiting and led to study termination.",
keywords = "AZD1480, JAK2 mutation, Myelofibrosis",
author = "Srdan Verstovsek and Ronald Hoffman and John Mascarenhas and Soria, {Jean Charles} and Ratislav Bahleda and Patricia McCoon and Weifeng Tang and Jorge Cortes and Hagop Kantarjian and Vincent Ribrag",
year = "2015",
month = "2",
day = "1",
doi = "10.1016/j.leukres.2014.11.018",
language = "English (US)",
volume = "39",
pages = "157--163",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - A phase I, open-label, multi-center study of the JAK2 inhibitor AZD1480 in patients with myelofibrosis

AU - Verstovsek, Srdan

AU - Hoffman, Ronald

AU - Mascarenhas, John

AU - Soria, Jean Charles

AU - Bahleda, Ratislav

AU - McCoon, Patricia

AU - Tang, Weifeng

AU - Cortes, Jorge

AU - Kantarjian, Hagop

AU - Ribrag, Vincent

PY - 2015/2/1

Y1 - 2015/2/1

N2 - The anti-tumor activity of AZD1480, a potent, selective inhibitor of Janus-associated kinases 1 and 2, was demonstrated in preclinical models of myeloproliferative neoplasms. In a phase I clinical study, 35 patients with myelofibrosis received 2.5-70. mg AZD1480 orally once daily (QD) or 10 or 15. mg twice daily (BID) continuously during repeated 28-day cycles. Two patients experienced dose-limiting toxicities: one patient in the 2.5. mg QD cohort had a grade 3 lung infiltration/acute pneumonia, and one patient receiving 50. mg QD had grade 3 presyncope. Dosing was stopped at 70. mg QD after the first patient experienced an adverse neurological event (AE) and evidence of low-grade neurological toxicity in patients on lower doses after the initial month of therapy became apparent. The most common AZD1480-related AEs were dizziness and anemia. AZD1480 was absorbed quickly and eliminated from the plasma rapidly, with a mean terminal half-life of 2.45-8.06. h; accumulation was not observed after repeated daily dosing for 28 days. Four patients showed evidence of clinical improvement based on IWG-MRT 2006 criteria. AZD1480 was relatively well tolerated, however, low-grade, reversible neurological toxicity was therapy limiting and led to study termination.

AB - The anti-tumor activity of AZD1480, a potent, selective inhibitor of Janus-associated kinases 1 and 2, was demonstrated in preclinical models of myeloproliferative neoplasms. In a phase I clinical study, 35 patients with myelofibrosis received 2.5-70. mg AZD1480 orally once daily (QD) or 10 or 15. mg twice daily (BID) continuously during repeated 28-day cycles. Two patients experienced dose-limiting toxicities: one patient in the 2.5. mg QD cohort had a grade 3 lung infiltration/acute pneumonia, and one patient receiving 50. mg QD had grade 3 presyncope. Dosing was stopped at 70. mg QD after the first patient experienced an adverse neurological event (AE) and evidence of low-grade neurological toxicity in patients on lower doses after the initial month of therapy became apparent. The most common AZD1480-related AEs were dizziness and anemia. AZD1480 was absorbed quickly and eliminated from the plasma rapidly, with a mean terminal half-life of 2.45-8.06. h; accumulation was not observed after repeated daily dosing for 28 days. Four patients showed evidence of clinical improvement based on IWG-MRT 2006 criteria. AZD1480 was relatively well tolerated, however, low-grade, reversible neurological toxicity was therapy limiting and led to study termination.

KW - AZD1480

KW - JAK2 mutation

KW - Myelofibrosis

UR - http://www.scopus.com/inward/record.url?scp=84921434895&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921434895&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2014.11.018

DO - 10.1016/j.leukres.2014.11.018

M3 - Article

C2 - 25530567

AN - SCOPUS:84921434895

VL - 39

SP - 157

EP - 163

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 2

ER -